It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. After-hours trades for Syndax Pharmaceuticals Inc. (SNDX) shows that investor sentiment remained broken, with the stock’s consolidated last price falling by -$0.04, or -0.16%, to $25.56. The Syndax Pharmaceuticals Inc. has recorded 12,673 volume in the after hours trading session. The stock was recently discussed on Yahoo Finance as it revealed that Syndax Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares.
Syndax Pharmaceuticals Inc. is listed on the NASDAQ in the Healthcare sector while operating in the Biotechnology industry. At the end of the last regular session, the stock closed at $25.60 and fluctuated between $26.35 as its day high and $25.59 as its day low. The current market capitalization of Syndax Pharmaceuticals Inc. is $1.70B. A total of 1.29 million shares were traded on the day, compared to an average of 872.04K shares.
Insider trades are also considered as indicators of how a stock will perform in the future, in addition to stock predictions. During the recent three months, SNDX has seen 9 BUY and 9 SELL insider trades, representing the acquisition of 72,770 and the disposition of 72,770 shares. Over the last 12 months, there were 49 BUYs and 39 SELLs from insiders. Insiders purchased 1,082,136 shares during that period but sold 905,779.
In the most recent transaction, Ordentlich Peter sold 17,200 shares of SNDX for 25.05 per share on Dec 02. After the transaction, the Chief Scientific Officer now owns 265 company shares. In a previous transaction on Dec 01, Ordentlich Peter sold 7,800 shares at 25.01 per share. SNDX shares that Chief Scientific Officer owns now total 265.
Among the insiders who sold shares, Katkin Keith disposed of 29,899 shares on Oct 06 at a per-share price of $25.90. This resulted in the Director holding 32,000 shares of SNDX after the transaction. In another insider transaction, Metzger Michael A sold 16,231 shares at $25.29 per share on Oct 06. Company shares held by the Chief Executive Officer now total 17,659.
Despite rarely being accurate, price targets can exert some form of influence at times, and are often regarded as valuable by markets. According to analysts who have offered 12-month price targets for SNDX in the last 3 months, the mean price target is $34.13 with high estimates of $41.00 and low estimates of $29.00. In terms of 52-week highs and lows, SNDX has a high of $26.51 and a low of $13.27.
As of this writing, SNDX has an earnings estimate of -$0.63 per share for the current quarter. EPS was calculated based on a consensus of 6 estimates, with a high estimate of -$0.6 per share and a lower estimate of -$0.66.
Balance Sheet Annually/Quarterly
As well as showing the assets and liabilities of the company, the balance sheet also shows the amount invested in equity by investors. Investors can analyze a company’s future prospects by calculating its financial ratios based on this information.
After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. Currently, 9 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for SNDX is Overweight with a score of 5.00. A total of 7 analysts rated the stock as Buy while 2 rated it as Overweight while 0 rated it as Hold. Among the other participants, 0 thought the stock was Underweight and 0 thought it should be Sold.